These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Kresken M; Hafner D; Mittermayer H; Verbist L; Bergogne-Bérézin E; Giamarellou H; Esposito S; van Klingeren B; Kayser FH; Reeves DS Infection; 1994; 22 Suppl 2():S90-8. PubMed ID: 7927836 [TBL] [Abstract][Full Text] [Related]
6. The epidemiology of bacterial resistance to quinolones. Acar JF; O'Brien TF; Goldstein FW; Jones RN Drugs; 1993; 45 Suppl 3():24-8. PubMed ID: 7689447 [TBL] [Abstract][Full Text] [Related]
8. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV. Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures. Stein GE Pharmacotherapy; 2005 Oct; 25(10 Pt 2):44S-54S. PubMed ID: 16178675 [TBL] [Abstract][Full Text] [Related]
11. Increasing prevalence of antimicrobial resistance among organisms isolated from blood culture in a Singapore hospital. Kumarasinghe G; Chow C; Yin LH; Hong SY; Bassett DC Southeast Asian J Trop Med Public Health; 1994 Mar; 25(1):116-22. PubMed ID: 7825001 [TBL] [Abstract][Full Text] [Related]
12. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095 [TBL] [Abstract][Full Text] [Related]
14. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424 [TBL] [Abstract][Full Text] [Related]
15. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp. Maurin M; Abergel C; Raoult D Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229 [TBL] [Abstract][Full Text] [Related]
16. Gatifloxacin: a review of its use in the management of bacterial infections. Perry CM; Ormrod D; Hurst M; Onrust SV Drugs; 2002; 62(1):169-207. PubMed ID: 11790160 [TBL] [Abstract][Full Text] [Related]
17. Resistance patterns among nosocomial pathogens: trends over the past few years. Jones RN Chest; 2001 Feb; 119(2 Suppl):397S-404S. PubMed ID: 11171776 [TBL] [Abstract][Full Text] [Related]
18. High-dose intravenous fluoroquinolones in the treatment of severe infections. Modai J J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789 [TBL] [Abstract][Full Text] [Related]